Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse

Molecular Therapy

Volumn 15, Issue 9, 2007, Pages 1587-1592

  Fletcher, Sue ^a   Honeyman, Kaite ^a   Fall, Abbie M ^a   Harding, Penny L ^a   Johnsen, Russell D ^a   Steinhaus, Joshua P ^a   Moulton, Hong M ^b   Iversen, Patrick L ^b   Wilton, Stephen D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b AVI BioPharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE; DYSTROPHIN; PHOSHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BECKER MUSCULAR DYSTROPHY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHY; EXON; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONSENSE MUTATION; NONVIRAL GENE DELIVERY SYSTEM; OPEN READING FRAME; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE DRUG DOSE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DYSTROPHIN; EXONS; GENE EXPRESSION; GENE THERAPY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED MDX; MORPHOLINES; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34547691961     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300245     Document Type: Article

References (48)

1. Wilton, SD and Fletcher, S (2005). RNA splicing manipulation: Strategies to modify gene expression for a variety of therapeutic outcomes. Curr Gene Ther 5: 467-483.
2. Wilton, SD and Fletcher, S (2005). Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now? Neuromuscul Disord 15: 399-402.
3. van Deutekom, JC (2005). Gene therapy: The 'pro-sense' approach to Duchenne muscular dystrophy. Eur J Hum Genet 13: 518-519.
4. van Deutekom, JC and van Ommen, GJ (2003). Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4: 774-783.
5. Emery, AE (1989). Clinical and molecular studies in Duchenne muscular dystrophy. Prog Clin Biol Res 306: 15-28.
6. Emery, AE (2002). Muscular dystrophy into the new millennium. Neuromuscul Disord 12: 343-349.
7. Den Dunnen, JT, Grootscholten, PM, Bakker, E, Blonden, LA, Ginjaar, HB, Wapenaar, MC et al. (1989). Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 45: 835-847.
8. Muntoni, F, Torelli, S and Ferlini, A (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2: 731-740.
9. Fajkusova, L, Lukas, Z, Tvrdikova, M, Kuhrova, V, Hajek, J and Fajkus, J (2001). Novel dystrophin mutations revealed by analysis of dystrophin mRNA: Alternative splicing suppresses the phenotypic effect of a nonsense mutation. Neuromuscul Disord 11: 133-138.
10. Roberts, RG, Gardner, RJ and Bobrow, M (1994). Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations. Hum Mutat 4: 1-11.
11. Monaco, AP, Bertelson, CJ, Liechti-Gallati, S, Moser, H and Kunkel, LM (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
12. Comi, GP, Prelle, A, Bresolin, N, Moggio, M, Bardoni, A, Gallanti, A et al. (1994). Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 117 (Pt 1): 1-14.
13. England, SB, Nicholson, LV, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343 180-182.
14. Chelly, J, Gilgenkrantz, H, Lambert, M, Hamard, G, Chafey, P, Recan, D et al. (1990). Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 63: 1239-1248.
15. Bosone, I, Bortolotto, S, Mongini, T, Doriguzzi, C, Chiado-Piat, L, Ugo, I et al. (2001). Late onset and very mild course of Xp21 Becker type muscular dystrophy. Clin Neuropathol 20: 196-199.
16. Mirabella, M, Galluzzi, G, Manfredi, G, Bertini, E, Ricci, E, De Leo, R et al. (1998). Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology 51 592-595.
17. Lu, QL, Morris, GE, Wilton, SD, Ly, T, Artem'yeva, OV, Strong, P et al. (2000). Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 148: 985-996.
18. Wilton, SD, Dye, DE, Blechynden, LM and Laing, NG (1997). Revertant fibres: A possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord 7: 329-335.
19. Sherratt, TG, Vulliamy, T, Dubowitz, V, Sewry, CA and Strong, PN (1993). Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 53: 1007-1015.
20. Thanh, LT, Nguyen, TM, Helliwell, TR and Morris, GE (1995). Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 56: 725-731.
21. Wallgren-Pettersson, C, Jasani, B, Rosser, LG, Lazarou, LP, Nicholson, LV and Clarke, A (1993). Immunohistological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibres in Xp21 muscular dystrophy of Duchenne-type severity. J Neurol Sci 118: 56-63.
22. Aartsma-Rus, A, Kaman, WE, Bremmer-Bout, M, Janson, AA, den Dunnen, JT, van Ommen, GJ et al. (2004). Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11: 1391-1398.
23. Fletcher, S, Honeyman, K, Fall, AM, Harding, PL, Johnsen, RD and Wilton, SD (2006). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotice. J Gene Med 8: 207-216.
24. Gebski, BL, Errington, SJ, Johnsen, RD, Fletcher, S and Wilton, SD (2005). Terminal antisense oligonucleotice modifications can enhance induced exon skipping Neuromuscul Disord 15: 622-629.
25. Gebski, BL, Mann, CJ, Fletcher, S and Wilton, SD (2003). Morpholino antisense oligonucleotice induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12: 1801-1811.
26. Youngblood, IDS, Hatlevig, SA, Hassinger, JN, Iversen, PL and Moulton, HM (2007). Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem 18: 50-60.
27. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
28. Mann, CJ, Honeyman, K, Cheng, AJ, Ly, T, Lloyd, F, Fletcher, S et al. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98: 42-47.
29. Mann, CJ, Honeyman, K, McClorey, G, Fletcher, S and Wilton, SD (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4: 644-654.
30. Bogdanovich, S, Perkins, KJ, Krag, TO and Khurana, TS (2004). Therapeutics for Duchenne muscular dystrophy: Current approaches and future directions. J Mol Med 82: 102-115.
31. Biggar, WD, Klamut, HJ, Demacio, PC, Stevens, DJ and Ray, PN (2002). Duchenne muscular dystrophy: Current knowledge, treatment, and future prospects. Clin Orthop Relat Res 401: 88-106.
32. Muntoni, F, Fisher, I, Morgan, JE and Abraham, D (2002). Steroids in Duchenne muscular dystrophy: From clinical trials to genomic research. Neuromuscul Disord 12 (Suppl. 1): S162-S165.
33. Eagle, M, Baudouin, SV, Chandler, C, Giddings, DR, Bullock, R and Bushby, K (2002). Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12: 926-929.
34. Aartsma-Rus, A, Janson, AA, Kaman, WE, Bremmer-Bout, M, van Ommen, GJ, den Dunnen, JT et al. (2004). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74: 83-92.
35. Aartsma-Rus, A, Janson, AA, Kaman, WE, Bremmer-Bout, M, den Dunnen, JT, Baas, F et al. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12: 907-914.
36. Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014.
37. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotice restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203.
38. Iversen, PL, Arora, V, Acker, AJ, Mason, DH and Devi, GR (2003). Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin Cancer Res 9: 2510-2519.
39. Iversen, PL (2001). Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 3: 235-238.
40. Summerton, J (1999). Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta 1489 141-158.
41. Muntoni, F, Mateddu, A, Marchei, F, Clerk, A and Serra, G (1993). Muscular weakness in the mdx mouse. J Neurol Sci 120: 71-77.
42. van Deutekom, JC, Bremmer-Bout, M, Janson, AA, Ginjaar, IB, Baas, F, den Dunnen, JT et al. (2001). Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10: 1547-1554.
43. McClorey, G, Fall, AM, Moulton, HM, Iversen, PL, Rasko, JE, Ryan, M et al. (2006). Induced exon skipping in human muscle explants. Neuromusc Disorders 16: 583-590.
44. Goyenvalle, A, Vulin, A, Fougerousse, F, Leturcq, F, Kaplan, JC, Garcia, L et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306: 1796-1799.
45. Abes, S, Moulton, HM, Clair, P, Prevot, F, Youngblood, DS, Wu, RP et al. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptice allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116: 304-313.
46. McClorey, G, Moulton, HM, Iversen, PL, Fletcher, S and Wilton, SD (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13: 1373-1381.
47. Bulfield, G, Siller, WG, Wight, PA and Moore, KJ (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81: 1189-1192.
48. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244: 1578-1580.